← Leaderboards
Sander Michel Houten
Icahn School Of Medicine At Mount Sinai
$3,775,555
Attributed
$6,256,454
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,256,454 · 7
By mechanism
R01$4,986,338 · 3
R21$931,532 · 2
R03$338,584 · 2
Top collaborators
- Robert J Devita10 shared
- Michael Block Lazarus4 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Michael Block Lazarus$6,195,746
- Robert J Devita$8,217,526
Others in their field
Other Emerging Leaders on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Jacob Ruff · Cornell University$22,500,000
- Elke Arenholz · Cornell University$14,750,000
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$14,335,772
- Amitinder Kaur · Tulane University Of Louisiana$12,771,713
Research focus
EnzymesBiochemicalResearch PersonnelNeonatal ScreeningNovel TherapeuticsDietary InterventionCell LineHereditary DiseaseDefectScreening ProgramPhenotypeCarnitine SupplementationAcuteMouse ModelRare DiseasesClinically SignificantOxidoreductaseBaseCommunitiesGlutaryl-Coa DehydrogenaseHigh Throughput ScreeningAcidsCaregiversGlutaric Acidemia
Grant awards (16)
Targeting succinyl-CoA:glutarate-CoA transferase as a novel therapeutic strategy for glutaric aciduria type 1$726,266
R01 · FY2025 · HD · contact PI
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$725,640
R01 · FY2025 · HD · contact PI
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$718,385
R01 · FY2024 · HD · contact PI
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$725,595
R01 · FY2023 · HD · contact PI
Substrate reduction as a novel therapeutic strategy for Glutaric Aciduria Type 1$169,000
R21 · FY2022 · HD · contact PI
A novel treatment option for disorders of propionate metabolism$84,500
R03 · FY2022 · HD · contact PI
Substrate reduction as a novel therapeutic strategy for Glutaric Aciduria Type 1$296,407
R21 · FY2021 · HD · contact PI
A novel treatment option for disorders of propionate metabolism$84,584
R03 · FY2021 · HD · contact PI
Novel pathophysiological insights into mitochondrial fatty acid oxidation disorders$503,244
R01 · FY2020 · DK · contact PI
Novel pathophysiological insights into mitochondrial fatty acid oxidation disorders$531,899
R01 · FY2019 · DK · contact PI
Novel pathophysiological insights into mitochondrial fatty acid oxidation disorders$531,471
R01 · FY2018 · DK · contact PI
Novel Treatment Options for Glutaric Aciduria$169,500
R21 · FY2018 · HD · contact PI
Genetic validation of DHTKD1 as a therapeutic target for the treatment of Glutaric Aciduria type 1$84,750
R03 · FY2018 · HD · contact PI
Novel pathophysiological insights into mitochondrial fatty acid oxidation disorders$523,838
R01 · FY2017 · DK · contact PI
Novel Treatment Options for Glutaric Aciduria$296,625
R21 · FY2017 · HD · contact PI
Genetic validation of DHTKD1 as a therapeutic target for the treatment of Glutaric Aciduria type 1$84,750
R03 · FY2017 · HD · contact PI